EUCTR2016-003616-13-ES进行中（未招募）1 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, ALK or NTRK1-3 gene fusion.
- •- Subject must have a documented ROS1, ALK or NTRK1-3 gene fusion that has been identified by local testing AND that has been prospectively confirmed by a central diagnostic laboratory selected by the Sponsor to determine molecular eligibility PRIOR to enrollment.
- •- Subjects with advanced solid tumors harboring ALK, ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met:
- •EXP-1: ROS1 TKI-naïve ROS1+ NSCLC (n=55).
- •No prior exposure to a ROS1 TKI is allowed.
- •Up to one prior line of chemotherapy OR immunotherapy is allowed (chemo- or immunotherapy-based combination regimen is considered as one line of treatment).
- •EXP-2: 1 Prior ROS1 TKI ROS1+ NSCLC (n=100).
- •Disease progression, unresponsive, or intolerant to one prior line of a ROS1 TKI.
- •ROS1 TKIs used in a prior line of treatment are limited to crizotinib, ceritinib, entrectinib, or lorlatinib. Note: Any previous exposure to a ROS1 TKI is considered as one prior line of TKI treatment (e.g., if the same ROS1 TKI was given before and after a chemotherapy or other systemic therapy, it is considered as 2 prior TKIs and the subject would not be eligible for EXP-2).
- •Up to one prior line of chemotherapy OR immunotherapy before or after a ROS1 TKI is allowed (chemo- or immunotherapy-based ombination regimen is considered as one line of treatment).
- •EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (n=40).
- •Disease progression, unresponsive, or intolerant to 2 prior lines of a ROS1 TKI treatment.
- •ROS1 TKIs used in prior lines of treatment are limited to crizotinib, ceritinib, entrectinib, lorlatinib, brigatinib, ensartinib, or cabozantinib. Other prior ROS1 TKI agents that are not listed may be allowed after discussion with the Sponsor Medical Monitor. Note: Any previous exposure to a ROS1 TKI is considered as one prior line of TKI treatment (e.g., if 2 different ROS1 TKIs are utilized, or the same ROS1 TKI was given before and after a chemotherapy or other systemic therapy, it is considered as 2 prior TKIs and the subject would be eligible).
- •Up to one prior line of chemotherapy OR immunotherapy pre-TKI or post-TKI is allowed (chemo- or immunotherapy-based combination regimen is considered as one line of treatment).
- •EXP-4: ROS1 or ALK TKI-naïve ROS1+ or ALK+ solid tumors (non-NSCLC) (n=12-26).
- •No prior exposure to a ROS1 or ALK TKI is allowed.
- •Up to 2 prior lines of chemo or immunotherapy are allowed (chemo- or immunotherapy-based combination regimen is considered as one line of treatment).
- •EXP-5: TRK TKI-naïve NTRK+ solid tumors (n=55).
- •No prior exposure to a TRK TKI is allowed.
- •Any number of prior lines of chemo or immunotherapy is allowed.
- •EXP-6: TRK TKI-pretreated NTRK+ solid tumors (n=40).
- •Disease progression, unresponsive, or intolerant to 1 or 2 prior TRK TKIs.
- •TRK TKIs used in prior lines of treatment are limited to entrectinib, larot
排除标准
- •1. Concurrent participation in another therapeutic clinical trial.
- •2. Symptomatic brain metastases or leptomeningeal involvement.
- •3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.
- •4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (=10 fractions) must have been completed at least 48 hours prior to study entry.
- •5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class = II), cerebrovascular accident or transient ischemic attack, symptomatic
- •bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of CTCAE grade =2.
- •6. Any of the following cardiac criteria:
- •Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value
- •Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec)
- •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
- •7. Known active infections requiring ongoing treatment (bacterial, fungal, viral including human immunodeficiency virus positivity).
- •8. Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
- •9. Peripheral neuropathy, paresthesia, dizziness, dysgeusia, muscle weakness, ataxia grade =2.
- •10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.
- •11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study, or could compromise protocol objectives in the opinion of the Investigator and/or Turning Point Therapeutics.
- •12. Current use or anticipated need for drugs that are known to be strong CYP3A inhibitors or inducers as listed in Appendix 5 of the protocol.
研究者
相似试验
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.Advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003616-13-DETurning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb company)630
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003616-13-BETurning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb company)630
招募中
2 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Advanced solid Tumors harboring ALK, ROS1 or NTRK1-3 rearrangementsAdvanced solid tumors. CancerNL-OMON54586Turning Point Therapeutics (a wholly owned subsidiary of Bristol Myers Squibb company)23
进行中（未招募）
1 期
Phase 1/2 Open Label solid tumour Safety and Tolerability study.advanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2016-003616-13-GBTurning Point Therapeutics, Inc.320
招募中
1 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPatients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsJPRN-jRCT2011210009Minal Mehta, MBBS20